Bellicum pharmaceuticals to present early phase 1 results for bpx-601 in prostate cancer at asco 2023 genitourinary cancers symposium

Houston, jan. 19, 2023 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a phase 1 clinical trial for bpx-601, its lead gocar-t® product candidate, has been accepted for poster presentation at the 2023 american society of clinical oncology genitourinary cancers symposium (asco gu). the meeting is being held february 16-18, 2023 in san francisco and virtually. the ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer.
BLCM Ratings Summary
BLCM Quant Ranking